Lupin gets EIR from USFDA for Aurangabad unit

New Delhi: Drug firm Lupin said it has received establishment inspection report (EIR) from the US health regulator for its Aurangabad plant in Maharashtra.

It has received notification that the inspection carried out by the United States Food and Drug Administration (USFDA) in April 2017 at its Aurangabad facility is now closed and the agency has issued an EIR, Lupin said in a statement.

"This closes all outstanding USFDA inspections at Lupin's Aurangabad facility", it added.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biotechnology products, and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds

The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds the global leadership position in the Anti-TB segment.